BCLI – Brainstorm Cell Therapeutics, Inc.
Brainstorm Cell Therapeutics InBCLI
$0.69Name : Brainstorm Cell Therapeutics In
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $6,788,813.00
EPSttm : -2.01
Brainstorm Cell Therapeutics In
$0.69
0.65%$0.0045Float Short %
9.16
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
EPS Last/This Y
0.71
EPS This/Next Y
0.16
Price
0.71
Target Price
20.68
Analyst Recom
3
Performance Q
50.39
Relative Volume
Beta
0.14
Ticker: BCLI
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-04 | BCLI | 1.16 | N/A | N/A | 0 |
| 2025-07-07 | BCLI | 1.15 | N/A | N/A | 0 |
| 2025-07-08 | BCLI | 1.31 | N/A | N/A | 0 |
| 2025-07-09 | BCLI | 1.25 | N/A | N/A | 0 |
| 2025-07-10 | BCLI | 1.215 | N/A | N/A | 0 |
| 2025-07-11 | BCLI | 1.1893 | N/A | N/A | 0 |
| 2025-07-14 | BCLI | 1.2 | N/A | N/A | 0 |
| 2025-07-15 | BCLI | 1.205 | N/A | N/A | 0 |
| 2025-07-16 | BCLI | 1.201 | N/A | N/A | 0 |
| 2025-07-17 | BCLI | 1.18 | N/A | N/A | 0 |
| 2025-07-18 | BCLI | 0.84 | N/A | N/A | 0 |
| 2025-07-21 | BCLI | 0.79 | N/A | N/A | 0 |
| 2025-07-22 | BCLI | 0.6851 | N/A | N/A | 0 |
| 2025-07-23 | BCLI | 0.69 | N/A | N/A | 0 |
| 2025-07-24 | BCLI | 0.6675 | N/A | N/A | 0 |
| 2025-07-25 | BCLI | 0.702 | N/A | N/A | 0 |
| 2025-07-28 | BCLI | 0.744 | N/A | N/A | 0 |
| 2025-07-29 | BCLI | 0.7499 | N/A | N/A | 0 |
| 2025-07-30 | BCLI | 0.73 | N/A | N/A | 0 |
| 2025-07-31 | BCLI | 0.6849 | N/A | N/A | 0 |
| 2025-08-01 | BCLI | 0.691 | N/A | N/A | 0 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-04 | BCLI | 1.16 | 45.0 | - | -1.60 |
| 2025-07-07 | BCLI | 1.15 | 45.0 | - | -1.60 |
| 2025-07-08 | BCLI | 1.31 | 45.0 | - | -1.60 |
| 2025-07-09 | BCLI | 1.24 | 45.0 | - | -1.60 |
| 2025-07-10 | BCLI | 1.22 | 45.0 | - | -1.60 |
| 2025-07-11 | BCLI | 1.20 | 45.0 | - | -1.60 |
| 2025-07-14 | BCLI | 1.20 | 45.0 | - | -1.60 |
| 2025-07-15 | BCLI | 1.20 | 45.0 | - | -1.60 |
| 2025-07-16 | BCLI | 1.20 | 45.0 | - | -1.60 |
| 2025-07-17 | BCLI | 1.17 | 45.0 | - | -1.60 |
| 2025-07-18 | BCLI | 1.17 | 45.0 | - | -1.60 |
| 2025-07-21 | BCLI | 0.84 | 45.0 | - | -1.60 |
| 2025-07-22 | BCLI | 0.74 | 45.0 | - | -1.60 |
| 2025-07-23 | BCLI | 0.67 | 45.0 | - | -1.60 |
| 2025-07-24 | BCLI | 0.69 | 45.0 | - | -1.60 |
| 2025-07-25 | BCLI | 0.69 | 45.0 | - | -1.60 |
| 2025-07-28 | BCLI | 0.72 | 45.0 | - | -1.60 |
| 2025-07-29 | BCLI | 0.74 | 45.0 | - | -1.60 |
| 2025-07-30 | BCLI | 0.74 | 45.0 | - | -1.60 |
| 2025-07-31 | BCLI | 0.73 | 45.0 | - | -1.60 |
| 2025-08-01 | BCLI | 0.71 | 45.0 | - | -1.60 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-04 | BCLI | 0.00 | 0.32 | 6.06 |
| 2025-07-07 | BCLI | 0.00 | 0.32 | 6.06 |
| 2025-07-08 | BCLI | 0.00 | 0.32 | 6.06 |
| 2025-07-09 | BCLI | 0.00 | 0.32 | 6.06 |
| 2025-07-10 | BCLI | 0.00 | 0.32 | 6.06 |
| 2025-07-11 | BCLI | 0.00 | 0.32 | 7.91 |
| 2025-07-14 | BCLI | 0.00 | 0.32 | 7.91 |
| 2025-07-15 | BCLI | 0.00 | 0.32 | 7.91 |
| 2025-07-16 | BCLI | 0.00 | 0.32 | 7.91 |
| 2025-07-17 | BCLI | 0.00 | 0.32 | 7.91 |
| 2025-07-18 | BCLI | 0.00 | 0.32 | 7.91 |
| 2025-07-21 | BCLI | 0.00 | 0.32 | 7.38 |
| 2025-07-22 | BCLI | 0.00 | 0.32 | 7.38 |
| 2025-07-23 | BCLI | 0.00 | 0.32 | 7.38 |
| 2025-07-24 | BCLI | 0.00 | 0.32 | 7.38 |
| 2025-07-25 | BCLI | 0.00 | 0.32 | 7.38 |
| 2025-07-28 | BCLI | 0.00 | 0 | 9.16 |
| 2025-07-29 | BCLI | 0.00 | 0 | 9.16 |
| 2025-07-30 | BCLI | 0.00 | 0 | 9.16 |
| 2025-07-31 | BCLI | 0.00 | 0 | 9.16 |
| 2025-08-01 | BCLI | 0.00 | 0 | 9.16 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.33
Avg. EPS Est. Next Quarter
-0.47
Insider Transactions
Institutional Transactions
Beta
0.14
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
32
Growth Score
19
Sentiment Score
15
Actual DrawDown %
99.7
Max Drawdown 5-Year %
-99.7
Target Price
20.68
P/E
Forward P/E
PEG
P/S
P/B
P/Free Cash Flow
EPS
-2.01
Average EPS Est. Cur. Y
-1.6
EPS Next Y. (Est.)
-1.44
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
Return on Equity vs Sector %
124.9
Return on Equity vs Industry %
143.6
EPS 1 7Days Diff
0.6
EPS 1 30Days Diff
0.61
EBIT Estimation
Brainstorm Cell Therapeutics InSector: Healthcare
Industry: Biotechnology
Employees: 29
Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
stock quote shares BCLI – Brainstorm Cell Therapeutics, Inc. Stock Price stock today
news today BCLI – Brainstorm Cell Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch BCLI – Brainstorm Cell Therapeutics, Inc. yahoo finance google finance
stock history BCLI – Brainstorm Cell Therapeutics, Inc. invest stock market
stock prices BCLI premarket after hours
ticker BCLI fair value insiders trading